胃复春片联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 胃复春片联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎的临床观察
TITLE:
摘要: 目的:观察胃复春片联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎的疗效和安全性。方法:894例慢性胃炎合并反流性食管炎患者随机分为对照组(407例)和观察组(487例)。对照组患者于早餐前30 min口服雷贝拉唑钠肠溶片10 mg,每日1次;观察组患者在对照组治疗的基础上给予胃复春片1 440 mg,口服,每日3次。两组患者疗程均为4~8周。观察两组患者的临床疗效,治疗前后反流性食管炎镜检分级情况 、症状总积分、抑郁量表(SAS)评分、焦虑量表(SDS)评分、生活质量量表(QOLS)评分、纽芬兰纪念大学幸福度量表(MUNSH)评分及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.01)。治疗前,两组患者反流性食管炎镜检各级例数,症状总积分、SAS评分、SDS评分、QOLS评分、MUNSH评分比较,差异均无统计学意义(P>0.05)。治疗后,两组患者反流性食管炎镜检各级例数均显著优于同组治疗前,且观察组优于对照组;症状总积分、SAS评分、SDS评分均显著低于同组治疗前,且观察组低于对照组;QOLS评分、MUNSH评分均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05或P<0.01)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胃复春片联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎较单用雷贝拉唑疗效显著,可缓解患者临床症状,安全性较好。
ABSTRACT: OBJECTIVE:To observe the efficacy and safety of weifuchun tablet combined with rabeprazole enteric-coated tablet in the treatment of chronic gastritis with reflux esophagitis. METHODS: 894 gastritis patients with reflux esophagitis were randomly divided into control group (407 cases) and observation group (487 cases). Control group was given 10 mg Rabeprazole enteric-coated tablet, once a day; observation group was additionally given 1 440 mg Weifuchun tablet, orally, 3 times a day. The treatment course for both groups was 4-8 weeks. Clinical efficacy, microscopic examination grading,total symptom scores, self-rating anxiety scores (SAS), self-rating depression scores (SDS), quality of life scale score(QOLS), Memorial University of Newfoundland Scale of Happiness score(MUNSH) of reflux esophagitis before and after treatment, and incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, the difference was statistically significant (P<0.01). Before treatment, there were no significant differences in the microscopic examination grading, symptom scores, SAS, SDS, QOLS and MUNSH scores between 2 groups (P>0.05); after treatment, the microscopic examination grading cases in 2 groups were significantly superior to before, observation group was superior to control group, total symptom scores, SAS and SDS scores were significantly lower than before, observation group was lower than control group, QOLS and MUNSH scores were significantly higher than before, observation group was higher than control group, the differences were statistically significant (P<0.05 of P<0.01). And there was no significant difference in the incidence of adverse reactions between 2 groups (P>0.05). CONCLUSIONS: Weifuchun tablet combined with rabeprazole enteric-coated tablet has better efficacy than only rabeprazole in the treatment of chronic gastritis with reflux esophagitis, it can relieve clinical symptoms of patients, with better safety.
期刊: 2016年第27卷第6期
作者: 邵学军
AUTHORS: SHAO Xuejun
关键字: 胃复春片;雷贝拉唑钠肠溶片;慢性胃炎;反流性食管炎;疗效;安全性
KEYWORDS: Weifuchun tablet; Rabeprazole enteric-coated tablet; Chronic gastritis; Reflux esophagitis; Efficacy; Safety
阅读数: 912 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!